Chaim Lebovits
Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. In the last two years, Mr. Lebovits has played a pivotal role in bringing additional strength and depth to the BrainStorm executive team, recruiting a number of biotech executives with critical clinical development and path-to-market experience to support the phase 3 development and regulatory filing of autologous MSC-NTF cells in ALS and MS.
In addition to his biotech experience, Mr. Lebovits is a senior executive on the board of a number of public and private companies involved in natural resource exploration projects around the world.